These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 9451001)
1. Different positioning of the ligand-binding domain helix 12 and the F domain of the estrogen receptor accounts for functional differences between agonists and antagonists. Nichols M; Rientjes JM; Stewart AF EMBO J; 1998 Feb; 17(3):765-73. PubMed ID: 9451001 [TBL] [Abstract][Full Text] [Related]
2. FLP recombinase/estrogen receptor fusion proteins require the receptor D domain for responsiveness to antagonists, but not agonists. Nichols M; Rientjes JM; Logie C; Stewart AF Mol Endocrinol; 1997 Jun; 11(7):950-61. PubMed ID: 9178754 [TBL] [Abstract][Full Text] [Related]
3. A genetically encoded fluorescent indicator capable of discriminating estrogen agonists from antagonists in living cells. Awais M; Sato M; Sasaki K; Umezawa Y Anal Chem; 2004 Apr; 76(8):2181-6. PubMed ID: 15080726 [TBL] [Abstract][Full Text] [Related]
4. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. Pike AC; Brzozowski AM; Hubbard RE; Bonn T; Thorsell AG; Engström O; Ljunggren J; Gustafsson JA; Carlquist M EMBO J; 1999 Sep; 18(17):4608-18. PubMed ID: 10469641 [TBL] [Abstract][Full Text] [Related]
5. Positive and negative discrimination of estrogen receptor agonists and antagonists using site-specific DNA recombinase fusion proteins. Logie C; Nichols M; Myles K; Funder JW; Stewart AF Mol Endocrinol; 1998 Aug; 12(8):1120-32. PubMed ID: 9717838 [TBL] [Abstract][Full Text] [Related]
6. Structural aspects of agonism and antagonism in the oestrogen receptor. Pike AC; Brzozowski AM; Walton J; Hubbard RE; Bonn T; Gustafsson JA; Carlquist M Biochem Soc Trans; 2000; 28(4):396-400. PubMed ID: 10961927 [TBL] [Abstract][Full Text] [Related]
7. Formation of a powerful capping motif corresponding to start of "helix 12" in agonist-bound estrogen receptor-alpha contributes to increased constitutive activity of the protein. Skafar DF Cell Biochem Biophys; 2000; 33(1):53-62. PubMed ID: 11322512 [TBL] [Abstract][Full Text] [Related]
8. Role of aspartate 351 in transactivation and active conformation of estrogen receptor alpha. Kim JH; Lee MH; Kim BJ; Kim JH; Han SJ; Kim HY; Stallcup MR J Mol Endocrinol; 2005 Dec; 35(3):449-64. PubMed ID: 16326832 [TBL] [Abstract][Full Text] [Related]
9. The human estrogen receptor alpha dimer binds a single SRC-1 coactivator molecule with an affinity dictated by agonist structure. Margeat E; Poujol N; Boulahtouf A; Chen Y; Müller JD; Gratton E; Cavailles V; Royer CA J Mol Biol; 2001 Feb; 306(3):433-42. PubMed ID: 11178903 [TBL] [Abstract][Full Text] [Related]
10. Understanding the human estrogen receptor-alpha using targeted mutagenesis. Skafar DF; Koide S Mol Cell Endocrinol; 2006 Feb; 246(1-2):83-90. PubMed ID: 16442702 [TBL] [Abstract][Full Text] [Related]
11. Crystal structure of the human LRH-1 DBD-DNA complex reveals Ftz-F1 domain positioning is required for receptor activity. Solomon IH; Hager JM; Safi R; McDonnell DP; Redinbo MR; Ortlund EA J Mol Biol; 2005 Dec; 354(5):1091-102. PubMed ID: 16289203 [TBL] [Abstract][Full Text] [Related]
12. Impaired helix 12 dynamics due to proline 892 substitutions in the androgen receptor are associated with complete androgen insensitivity. Elhaji YA; Stoica I; Dennis S; Purisima EO; Lumbroso R; Beitel LK; Trifiro MA Hum Mol Genet; 2006 Mar; 15(6):921-31. PubMed ID: 16449235 [TBL] [Abstract][Full Text] [Related]
13. Homology models of mu-opioid receptor with organic and inorganic cations at conserved aspartates in the second and third transmembrane domains. Zhorov BS; Ananthanarayanan VS Arch Biochem Biophys; 2000 Mar; 375(1):31-49. PubMed ID: 10683246 [TBL] [Abstract][Full Text] [Related]
14. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Shiau AK; Barstad D; Loria PM; Cheng L; Kushner PJ; Agard DA; Greene GL Cell; 1998 Dec; 95(7):927-37. PubMed ID: 9875847 [TBL] [Abstract][Full Text] [Related]
15. Different residues of the human estrogen receptor are involved in the recognition of structurally diverse estrogens and antiestrogens. Ekena K; Weis KE; Katzenellenbogen JA; Katzenellenbogen BS J Biol Chem; 1997 Feb; 272(8):5069-75. PubMed ID: 9030571 [TBL] [Abstract][Full Text] [Related]
16. Molecular sensors of estrogen receptor conformations and dynamics. Tamrazi A; Carlson KE; Katzenellenbogen JA Mol Endocrinol; 2003 Dec; 17(12):2593-602. PubMed ID: 12947047 [TBL] [Abstract][Full Text] [Related]
17. Modulation of nuclear receptor activity by the F domain. Patel SR; Skafar DF Mol Cell Endocrinol; 2015 Dec; 418 Pt 3():298-305. PubMed ID: 26184856 [TBL] [Abstract][Full Text] [Related]
18. Full-length estrogen receptor alpha and its ligand-binding domain adopt different conformations upon binding ligand. Bapat AR; Frail DE J Steroid Biochem Mol Biol; 2003 Aug; 86(2):143-9. PubMed ID: 14568565 [TBL] [Abstract][Full Text] [Related]
19. Allosteric control of ligand selectivity between estrogen receptors alpha and beta: implications for other nuclear receptors. Nettles KW; Sun J; Radek JT; Sheng S; Rodriguez AL; Katzenellenbogen JA; Katzenellenbogen BS; Greene GL Mol Cell; 2004 Feb; 13(3):317-27. PubMed ID: 14967140 [TBL] [Abstract][Full Text] [Related]
20. Crystal structure of a mutant hERalpha ligand-binding domain reveals key structural features for the mechanism of partial agonism. Gangloff M; Ruff M; Eiler S; Duclaud S; Wurtz JM; Moras D J Biol Chem; 2001 May; 276(18):15059-65. PubMed ID: 11278577 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]